Lexaria Bioscience Corp. (LEXX) stock
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
$4.03−0.46 (-10.24%)
Close on Nov 20, 2026Market cap $99.89MP/E –Yield –
Lexaria Bioscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Lexaria Bioscience's free cash flow for the twelve months ending May 31, 2026 was -$7.47M. For fiscal 2025 it was -$10.48M. The highest annual figure on record is -$663.95K in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | -$10.48M | – |
| FY2024 | Aug 31, 2024 | -$5.00M | – |
| FY2023 | Aug 31, 2023 | -$5.91M | – |
| FY2022 | Aug 31, 2022 | -$4.93M | – |
| FY2020 | Aug 31, 2020 | -$2.62M | – |
| FY2019 | Aug 31, 2019 | -$3.65M | – |
| FY2017 | Aug 31, 2017 | -$1.55M | – |
| FY2016 | Aug 31, 2016 | -$663.95K | – |
| FY2015 | Aug 31, 2015 | -$1.50M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | -$1.64M | – |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | -$2.20M | – |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | -$984.10K | – |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | -$2.64M | – |
| Q3 FY2025CQ2 2025 | May 31, 2025 | -$3.58M | – |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | -$1.50M | – |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | -$2.75M | – |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | -$1.93M | – |
| Q3 FY2024CQ2 2024 | May 31, 2024 | -$1.27M | – |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | -$619.61K | – |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | -$1.18M | – |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | -$1.62M | – |
| Q3 FY2023CQ2 2023 | May 31, 2023 | -$1.79M | – |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | -$1.24M | – |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | -$1.27M | – |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | -$1.18M | – |
| Q3 FY2022CQ2 2022 | May 31, 2022 | -$1.27M | – |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | -$1.28M | – |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | -$1.21M | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$809.53K | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$639.35K | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$555.08K | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$746.13K | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$1.30M | – |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -$921.57K | – |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -$687.15K | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$353.34K | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$603.50K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$488.09K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$100.99K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | -$260.77K | – |
See a number that looks wrong?